Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15012858rdf:typepubmed:Citationlld:pubmed
pubmed-article:15012858lifeskim:mentionsumls-concept:C0042216lld:lifeskim
pubmed-article:15012858lifeskim:mentionsumls-concept:C0521009lld:lifeskim
pubmed-article:15012858lifeskim:mentionsumls-concept:C0031154lld:lifeskim
pubmed-article:15012858lifeskim:mentionsumls-concept:C0009498lld:lifeskim
pubmed-article:15012858lifeskim:mentionsumls-concept:C0033684lld:lifeskim
pubmed-article:15012858lifeskim:mentionsumls-concept:C0442805lld:lifeskim
pubmed-article:15012858lifeskim:mentionsumls-concept:C0449297lld:lifeskim
pubmed-article:15012858lifeskim:mentionsumls-concept:C2587213lld:lifeskim
pubmed-article:15012858lifeskim:mentionsumls-concept:C1517004lld:lifeskim
pubmed-article:15012858pubmed:issue4lld:pubmed
pubmed-article:15012858pubmed:dateCreated2004-3-11lld:pubmed
pubmed-article:15012858pubmed:abstractTextComplement is one of the first immunological pathways activated in peritonitis. It functions to initiate and augment the innate immune response. Complement activation has also been shown to contribute to multiple organ failure after sepsis. Vaccinia virus complement control protein (VCP) is an immunomodulatory protein encoded by vaccinia virus and binds complement components C3b and C4b of the complement cascade to inhibit both the classical and alternative pathways of complement activation. This study investigates the effect of complement inhibition by recombinant (r) VCP on bacterial clearance after cecal ligation and puncture (CLP). Methods: Swiss Webster mice were intravenously given either 20 mg/kg rVCP in 0.2 mL of normal saline, or 0.2 mL of normal saline alone, at the time of CLP. After 4 and 18 h, samples of peritoneal washout, blood, liver, and lung were collected for bacteriology, myeloperoxidase (MPO) assay for neutrophil accumulation, differential cell counts, and interleukin (IL)12 ELISA. Statistical analysis was by Mann-Whitney U test for bacteriology, and analysis of variance (ANOVA) for MPO and IL-12 concentrations.lld:pubmed
pubmed-article:15012858pubmed:languageenglld:pubmed
pubmed-article:15012858pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15012858pubmed:citationSubsetIMlld:pubmed
pubmed-article:15012858pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15012858pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15012858pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15012858pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15012858pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15012858pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15012858pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15012858pubmed:statusMEDLINElld:pubmed
pubmed-article:15012858pubmed:issn1096-2964lld:pubmed
pubmed-article:15012858pubmed:authorpubmed-author:ScottMelanie...lld:pubmed
pubmed-article:15012858pubmed:authorpubmed-author:PeytonJames...lld:pubmed
pubmed-article:15012858pubmed:authorpubmed-author:CheadleWillia...lld:pubmed
pubmed-article:15012858pubmed:authorpubmed-author:KotwalGirish...lld:pubmed
pubmed-article:15012858pubmed:authorpubmed-author:BurchPhillip...lld:pubmed
pubmed-article:15012858pubmed:authorpubmed-author:JhaPuroshotta...lld:pubmed
pubmed-article:15012858pubmed:issnTypePrintlld:pubmed
pubmed-article:15012858pubmed:volume4lld:pubmed
pubmed-article:15012858pubmed:ownerNLMlld:pubmed
pubmed-article:15012858pubmed:authorsCompleteYlld:pubmed
pubmed-article:15012858pubmed:pagination317-26lld:pubmed
pubmed-article:15012858pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:15012858pubmed:meshHeadingpubmed-meshheading:15012858...lld:pubmed
pubmed-article:15012858pubmed:meshHeadingpubmed-meshheading:15012858...lld:pubmed
pubmed-article:15012858pubmed:meshHeadingpubmed-meshheading:15012858...lld:pubmed
pubmed-article:15012858pubmed:meshHeadingpubmed-meshheading:15012858...lld:pubmed
pubmed-article:15012858pubmed:meshHeadingpubmed-meshheading:15012858...lld:pubmed
pubmed-article:15012858pubmed:meshHeadingpubmed-meshheading:15012858...lld:pubmed
pubmed-article:15012858pubmed:meshHeadingpubmed-meshheading:15012858...lld:pubmed
pubmed-article:15012858pubmed:meshHeadingpubmed-meshheading:15012858...lld:pubmed
pubmed-article:15012858pubmed:meshHeadingpubmed-meshheading:15012858...lld:pubmed
pubmed-article:15012858pubmed:meshHeadingpubmed-meshheading:15012858...lld:pubmed
pubmed-article:15012858pubmed:meshHeadingpubmed-meshheading:15012858...lld:pubmed
pubmed-article:15012858pubmed:meshHeadingpubmed-meshheading:15012858...lld:pubmed
pubmed-article:15012858pubmed:meshHeadingpubmed-meshheading:15012858...lld:pubmed
pubmed-article:15012858pubmed:meshHeadingpubmed-meshheading:15012858...lld:pubmed
pubmed-article:15012858pubmed:meshHeadingpubmed-meshheading:15012858...lld:pubmed
pubmed-article:15012858pubmed:meshHeadingpubmed-meshheading:15012858...lld:pubmed
pubmed-article:15012858pubmed:meshHeadingpubmed-meshheading:15012858...lld:pubmed
pubmed-article:15012858pubmed:year2003lld:pubmed
pubmed-article:15012858pubmed:articleTitleVaccinia virus complement control protein increases early bacterial clearance during experimental peritonitis.lld:pubmed
pubmed-article:15012858pubmed:affiliationDepartments of Surgery, and Microbiology & Immunology, University of Louisville School of Medicine, and the Veterans Affairs Medical Center, Louisville, Kentucky 40292, USA.lld:pubmed
pubmed-article:15012858pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15012858pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed